[PE10] Poster Session 10
Atopic dermatitis 2

[PE10-7] Continued treatment with dupilumab (LIBERTY AD OLE) provides clinical benefits in most adults with moderate-to-severe atopic dermatitis not achieving optimal response to short-term treatment

Joo Young Roh¹, Young Lip Park², Chun Wook Park³, Zhen Chen⁴, Arima Kazuhiko⁵, Oh EunSil⁶, Brad Shumel⁴, Ana B Rossi⁷ (1.Gachon University, Gil Medical Center, Republic of Korea, 2.Soonchunhyang University, College of Medicine, Republic of Korea, 3.Hallym University, College of Medicine, Republic of Korea, 4.Regeneron Pharmaceuticals, Inc., USA, 5.Sanofi K.K., Japan, 6.Sanofi-aventis, Republic of Korea, 7.Sanofi Genzyme, USA)